论文部分内容阅读
该文从分析青海药用资源状况及开发现状入手,指出了青海医药产业应以市场为导向,建设中藏药药材种植基地,提升传统中藏药生产水平,以企业为主体加快体制创新为发展战略。在药材种植上,从84种地道地产药材中选择12种重点药材作为药材饮片开发和开展相关种植基地建设;在新药研发方面,心脑血管疾病、消化系统疾病、肝病、风湿类疾病、妇科类疾病是藏药5个具有治疗优势的病种,也是进一步开发的重点领域;生产基地的建设以组建大型藏药集团、中藏药集团、化学和特控药品集团、包装和医疗器械集团等为发展重点;政策保障上应建立新药开发基金、加强法规建设、建立完善的市场体制、将生态建设与基地建设并举、广泛开展科技交流与合作等措施。
This article starts with an analysis of the status and development status of medical resources in Qinghai, and points out that Qinghai’s pharmaceutical industry should be market-oriented, build a cultivation base for Tibetan medicines and herbs, raise the level of traditional Tibetan medicine production, and use enterprises as the main body to accelerate institutional innovation for development. strategy. In the cultivation of medicinal herbs, 12 kinds of key medicinal materials were selected from 84 real-estate medicinal herbs as medicinal materials to develop and carry out the construction of relevant planting bases; in the research and development of new drugs, cardiovascular and cerebrovascular diseases, digestive diseases, liver diseases, rheumatism, and gynecology Diseases are five diseases of Tibetan medicine that have advantages in treatment, and are also key areas for further development; the construction of production bases includes the establishment of large-scale Tibetan medicine group, China Tibet Pharmaceutical Group, chemical and special control medicine group, packaging and medical equipment group, etc. Development priorities; policy safeguards should establish new drug development funds, strengthen the construction of laws and regulations, establish a sound market system, combine ecological construction with base construction, and conduct extensive scientific and technological exchanges and cooperation.